Interview with Jeff Galvin, CEO & Founder of American Gene Technologies / Addimmune

Jeff Galvin is the CEO and Founder of American Gene Technologies®. He earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT™ after meeting Roscoe Brady at NIH.

Interview questions:

New Company | At the beginning of June, American Gene Technologies launched a new company, Addimmune. Please explain the rationale for the spinoff.

Milestones | What is the status of the clinical milestones?

Technology | Can you explain the technology that you have developed?

Cure | Is the solution a cure or treatment?

Patents | Can you tell us about your patent portfolio?

Team | Who are the other members of the team? Jeff Boyle, Chief Science Officer, Marcus Conant, Chief Medical Officer

Funding | Are you working on a Series A?

Connect with Jeff on LinkedIn

AGT is a gene and cell therapy company with a proprietary gene-delivery platform for rapid development of gene therapies to cure infectious diseases, cancers, and inherited disorders. Its mission is to transform people’s lives through genetic medicines that rid the body of disease. Safety data from American Gene Technologies’ Phase 1 HIV gene therapy clinical trial is published in the Frontiers in Medicine journal. In addition, the company has been granted broad patent protection for the technology used to make AGT103-T. Numerous other patents have been granted for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors, as well as other important innovations and discoveries that are useful across a wide variety of gene and cell therapy applications. American Gene Technologies has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. The company’s treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2025.

Recent News:

Edwin Warfield, CEO of, conducts CEO Interviews.

If you’re interested in a citybiz CEO Interview, please contact
Edwin Warfield –